内源性大麻素样系统与肥胖  

The endocannabinoid system and obesity

作　　者：王淼[1] 邹大进[1] 

机构地区：[1]第二军医大学长海医院内分泌科,上海200433

出　　处：《国际内分泌代谢杂志》2006年第1期29-31,共3页International Journal of Endocrinology and Metabolism

摘　　要：内源性大麻素样系统主要由内源性大麻素及其受体组成,后者分为CB1受体和CB2受体两种,激活后可引起摄食增加。与正常小鼠相比,CB1受体(-/-)小鼠的体重和脂肪明显减少,即使在致肥胖饮食条件下也不会发生肥胖或胰岛素抵抗。研究证实,CB1受体拮抗剂可通过中枢和外周两种机制抑制摄食并改善代谢;其中,利莫那班已进入Ⅲ期临床试验,可有效抑制食欲、减轻体重,并且尚未发现明显的副作用。The endocannabinoid system comprises endocannabinoid and two cloned subtypes of cannabinoid receptor, CB1 and CB2, which can stimulate appetite when activated. Compared with normal mice, the body weight and the mass of adipose tissue of CBI（ - / - ） mice decrease significantly. CBI（ - / - ） mice don＇t develope obesity and instdin resistance even given high-fat diet. Evidence suggested that CB1 antagonists can decrease appetite and improve metabolism through central and peripheral ways. Rimonabant, a CB1 antagonist, has been in phase Ⅲ clinical trials for treatment of obesity and can decrease appetite and weight in humans. No serious side effect of rimonabant has been reported yet.

关 键 词：内源性大麻素样系统 大麻素样受体1 肥胖 利莫那班 

分 类 号：R589.2[医药卫生—内分泌]